Dr Jeremie Calais reviews the VISION trial and the implications of the data in the treatment paradigm for metastatic castration-resistant prostate cancer (mCRPC). Alicia Morgans, MD: I am curious from ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Alkaline phosphatase (ALP) decline and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the REASSURE study. This ...

(RTTNews) - Swiss drug major Novartis AG (NVS) announced Tuesday positive result from its phase III VISION study evaluating the efficacy and safety of radioligand therapy 177Lu-PSMA-617 in patients ...

Men with adrenal-permissive HSD3B1 genotype and prostate cancer mortality: Results from the Veterans Affairs Health System Million Veteran Program. Parameter treated as *categorical or † continuous.

Novartis announced positive health-related quality of life (HRQoL) data from its phase III VISION study evaluating 177Lu-PSMA-617, an investigational targeted radioligand therapy, plus standard of ...

Prostate-specific membrane antigen (PSMA) is a protein found in small amounts in your prostate gland. When you have prostate cancer, you have many times more PSMA than normal. This makes PSMA a good ...

Getting your Trinity Audio player ready... “Patients suffering from metastatic CRPC who have progressed through contemporary hormonal treatments and chemotherapy have few meaningful therapeutic ...

Men who received 177 Lu-PSMA-617 plus best standard of care had a 38% reduction in risk of death (median OS benefit of 4 months) and a 60% reduction in the risk of radiographic disease progression or ...

EAST HANOVER, N.J. , June 3, 2021 /PRNewswire/ -- Novartis today announced that results of the Phase III VISION study evaluating 177 Lu-PSMA-617, a targeted radioligand therapy, plus best standard of ...

Men who received 177 Lu-PSMA-617 plus best standard of care had a 38% reduction in risk of death (median OS benefit of 4 months) and a 60% reduction in the risk of radiographic disease progression or ...